May 24, 2023 05:00 PM EDTUpdated 05:44 PM

Mirati’s drug sitravatinib flops PhIII in combo with Opdivo for certain lung cancer

Kyle LaHucik

Senior Reporter

Mirati Therapeutics’ path to a second drug approval will likely have to wait. The San Diego biotech company said Wednesday that its investigational lung cancer …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Mirati’s drug sitravatinib flops PhIII in combo with Opdivo for certain lung cancer

Kyle LaHucik

Senior Reporter

Sign up to read this article for free.

Executive Director, Marketing

Celldex Therapeutics

Hampton, NJ, USA

Makary, in one of first comments on FDA policy, floats new pathway for rare disease drugs

China startup injects CRISPR therapy into the brain for the first time

Trodelvy and Keytruda combo succeeds in Phase 3 breast cancer study

Roivant brings rare disease program closer as Immunovant CEO retires

FDA plans to ban pharma employees from serving on adcomms. The impact will be limited

ADSTILADRIN® (nadofaragene firadenovec-vncg) – A Growing Body of Clinical Data and Real-World Evidence

Mi­rati’s drug sitra­va­tinib flops PhI­II in com­bo with Op­di­vo for cer­tain lung can­cer

Senior Reporter

Sign up to read this article for free.

Celldex Therapeutics

Hampton, NJ, USA

Mirati’s drug sitravatinib flops PhIII in combo with Opdivo for certain lung cancer